Insilico Medicine Advances ISM5059 as a Novel NLRP3 Inhibitor for Systemic Inflammation Treatment Insilico Medicine has nominated ISM5059, a peripheral NLRP3 inhibitor, as a preclinical candidate for treating systemic inflammation, showcasing AI-driven drug discovery's potential.

Insilico Medicine Advances ISM5059 as a Novel NLRP3 Inhibitor for Systemic Inflammation Treatment #Hong_Kong #Insilico_Medicine #NLRP3 #ISM5059